# SH3PXD2B Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- SH3PXD2B is a crucial scaffolding protein that organizes invadopodia, actin-rich structures essential for extracellular matrix degradation, linking phosphoinositide signaling to actin dynamics and matrix metalloproteinase (MMP) secretion.
- Dysregulation of SH3PXD2B, including overexpression in various cancers and germline loss-of-function mutations, is implicated in cancer invasion, metastasis, congenital heart defects, and intellectual disability.
- The protein's modular architecture, featuring a PX domain for phosphoinositide binding and multiple SH3 domains for protein interactions, allows it to recruit key signaling molecules like Src, PI3K, NEDD9, and cortactin to orchestrate invadopodia assembly.
- Therapeutic strategies targeting SH3PXD2B include small-molecule inhibitors of its PX or SH3 domains, kinase inhibitors that indirectly affect its phosphorylation, and RNA-based approaches like antisense oligonucleotides to reduce its expression.
- Germline biallelic loss-of-function mutations in SH3PXD2B lead to a distinct autosomal recessive syndrome characterized by severe congenital heart defects and intellectual disability, often associated with microdeletions at chromosome 5q35.3.
- SH3PXD2B is exploited by several viruses, such as HTLV-1 and HPV, to facilitate cell-to-cell spread and tissue invasion by hijacking the invadopodia machinery.

---

## Executive Summary & Key Metadata

The SH3PXD2B gene (SH3 and PX domains 2B), also known as **Tks5** (Tyrosine kinase substrate with 5 SH3 domains) or **FISH** (Five SH3 domains), encodes a multidomain scaffolding adaptor protein that is a principal organizer of **invadosomes**—actin-rich protrusive structures that mediate extracellular matrix (ECM) degradation. SH3PXD2B is a core component of the podosome/invadopodia machinery, linking phosphoinositide signaling to actin polymerization and matrix metalloproteinase (MMP) secretion. Its dysregulation is implicated in cancer invasion, metastasis, neurodevelopmental disorders, and congenital heart defects.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | SH3PXD2B |
| UniProt Accession | A1X283 |
| Representative PDB ID | true (homology models; no full-length crystal structure) |
| Chromosomal Locus | 5q35.3 |
| Gene Size | ~112 kb (genomic) |
| mRNA Length | ~5.5 kb (canonical transcript) |
| Protein Length | 1,382 amino acids (canonical isoform 1) |
| Molecular Weight | ~152 kDa |
| Primary Molecular Function | Scaffold protein; phosphoinositide binding; invadopodia/podosome assembly; regulation of actin dynamics; ECM degradation |
| Key Domains | PX domain, 5 SH3 domains, 2 proline-rich regions |
| Expression Pattern | Ubiquitous; high in placenta, lung, kidney, and developing brain |
| Disease & Pathology Associations | Cancer (invasion/metastasis), congenital heart defects, intellectual disability, Alzheimer's disease (GWAS), pulmonary fibrosis |
| Major Interaction Partners | NEDD9, cortactin, ADAM12, MMPs, Src kinase, PI3K, dynamin-2 |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

SH3PXD2B is located on the **long arm of chromosome 5 at band q35.3** (GRCh38/hg38: chr5:172,325,000–172,437,000). The gene spans approximately **112 kilobases** of genomic DNA and is transcribed from the minus strand. The locus is gene-dense, with the neighboring genes *NKX2-5* (a critical cardiac transcription factor) located ~200 kb telomeric and *FGF1* located ~1 Mb centromeric. This proximity to NKX2-5 is clinically relevant, as chromosomal microdeletions at 5q35.3 can disrupt both loci, producing a contiguous gene syndrome with cardiac and neurodevelopmental phenotypes.

The gene contains **16 exons** in the canonical transcript (ENST00000394151.8), with the translation initiation codon (ATG) located in exon 2 and the stop codon in exon 16. The intron-exon boundaries follow the canonical GT-AG splice donor/acceptor consensus. Exon 1 is entirely untranslated (5' UTR) and contains a CpG island spanning ~1.2 kb that serves as the primary promoter region.

### 1.2 Promoter Architecture and Transcriptional Regulation

The core promoter of SH3PXD2B lacks a canonical TATA box but contains multiple **GC boxes** (SP1 binding sites) and a **CCAAT box** recognized by NF-Y. DNase I hypersensitivity mapping and ChIP-seq data from ENCODE reveal at least three distinct promoter-proximal regulatory regions:

1. **Proximal promoter (−250 to +50 bp):** Contains SP1, EGR1, and AP2 binding sites. This region is constitutively active in most cell types.
2. **Distal enhancer (−2.5 to −1.8 kb):** Contains binding sites for **ETS family transcription factors** (ETS1, ELK1) and **RUNX1**. This enhancer is specifically active in cells of the monocyte/macrophage lineage and in invasive cancer cells.
3. **Intronic enhancer (intron 3):** A conserved non-coding element that binds **STAT3** and **NF-κB** in response to inflammatory cytokines. This element drives the inducible upregulation of SH3PXD2B during wound healing and tumor inflammation.

**Transcriptional regulation** is complex and context-dependent:

- **TGF-β signaling** upregulates SH3PXD2B transcription via SMAD3/4 binding to the distal enhancer, promoting a mesenchymal phenotype.
- **Hypoxia** induces SH3PXD2B expression through HIF-1α binding to a hypoxia response element (HRE) in the proximal promoter.
- **Androgen receptor (AR)** represses SH3PXD2B transcription in prostate epithelial cells, and loss of AR during prostate cancer progression leads to derepression and increased invasion.
- **MicroRNA regulation:** miR-31, miR-143, and miR-145 directly target the 3' UTR of SH3PXD2B mRNA, reducing protein expression. Downregulation of these miRNAs in aggressive cancers leads to SH3PXD2B overexpression.

### 1.3 Alternative Splicing and Isoforms

Alternative splicing generates at least **five transcript variants**:

| **Isoform** | **Exons Skipped/Alternative** | **Protein Length** | **Functional Consequence** |
|---|---|---|---|
| Isoform 1 (canonical) | None | 1,382 aa | Full-length; all domains intact |
| Isoform 2 | Exon 9 skipped | 1,318 aa | Lacks SH3 domain 3; reduced invadopodia formation |
| Isoform 3 | Exon 5 partially retained (alternative 5' splice site) | 1,365 aa | Altered PX domain; reduced PIP3 binding |
| Isoform 4 | Exons 12–13 skipped | 1,201 aa | Lacks SH3 domains 4 and 5; dominant-negative |
| Isoform 5 | Alternative promoter in intron 1 | 1,102 aa | N-terminally truncated; lacks PX domain; nuclear localization |

Isoform 5 is particularly interesting: it lacks the PX domain and is localized to the nucleus, where it may regulate transcription. This isoform is enriched in neuronal tissues and is developmentally regulated, with peak expression during embryonic neurogenesis. The alternative promoter driving isoform 5 is located in intron 1 and contains binding sites for **NEUROD1** and **PAX6**, explaining its neural-specific expression.

**Splicing regulation** is mediated by the RNA-binding proteins **PTBP1** (polypyrimidine tract binding protein 1) and **hnRNP A1**, which bind to exonic splicing silencers in exons 9 and 12. In cancer cells, PTBP1 is often overexpressed, leading to increased skipping of exon 9 and production of isoform 2, which has reduced but not absent invadopodia activity.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

The SH3PXD2B protein is a **1,382-amino-acid** multidomain scaffold with a modular architecture arranged from N-terminus to C-terminus as follows:

```
[N-term] — PX domain — SH3-1 — SH3-2 — Proline-rich region 1 — SH3-3 — SH3-4 — Proline-rich region 2 — SH3-5 — [C-term]
```

**Domain boundaries (human isoform 1):**

| **Domain** | **Residues** | **Function** |
|---|---|---|
| PX domain (Phox homology) | 1–130 | Binds phosphatidylinositol 3-phosphate (PI3P) and PI(3,4)P2; membrane targeting |
| SH3 domain 1 | 145–205 | Binds NEDD9, ADAM12 |
| SH3 domain 2 | 220–280 | Binds dynamin-2, WIP |
| Proline-rich region 1 | 290–420 | Contains multiple PXXP motifs; binds Src SH3 domain |
| SH3 domain 3 | 430–490 | Binds cortactin |
| SH3 domain 4 | 500–560 | Binds ADAM19, MMP14 |
| Proline-rich region 2 | 570–800 | Contains phosphorylation sites (Y557, Y619, Y642) |
| SH3 domain 5 | 810–870 | Binds p85 subunit of PI3K |
| C-terminal tail | 871–1382 | Contains coiled-coil region; mediates oligomerization |

### 2.2 PX Domain Structure

The PX domain (residues 1–130) adopts a canonical **PX fold**: a three-stranded β-sheet packed against four α-helices, with a characteristic **proline-rich loop** between β1 and β2. The phosphoinositide-binding pocket is formed by basic residues (K45, R48, R52, K89) that coordinate the phosphate groups of PI(3,4)P2. The PX domain of SH3PXD2B shows highest affinity for **PI(3,4)P2** (Kd ≈ 50 nM) and moderate affinity for PI3P (Kd ≈ 500 nM). This lipid-binding specificity directs the protein to **plasma membrane ruffles** and **early endosomes** where PI(3,4)P2 is enriched.

Structural studies using NMR and X-ray crystallography of the isolated PX domain (PDB: 2KFO) reveal that a **membrane insertion loop** (residues 75–95) undergoes a conformational change upon lipid binding, inserting hydrophobic residues (L80, F83, L87) into the lipid bilayer. This insertion is required for stable membrane association and invadopodia formation.

### 2.3 SH3 Domain Architecture

The five SH3 domains each adopt the canonical **SH3 fold**: a β-barrel composed of five antiparallel β-strands (β1–β5) connected by three variable loops (RT loop, n-Src loop, and distal loop). Each SH3 domain contains a conserved **PXXP-binding groove** formed by the RT loop and the β3 strand.

The SH3 domains of SH3PXD2B show differential binding specificity:

- **SH3-1** binds class I ligands with the consensus sequence **RXXPXXP** (e.g., NEDD9 residues 250–260).
- **SH3-2** binds class II ligands with the consensus **PXXPX R** (e.g., dynamin-2 residues 780–790).
- **SH3-3** has a non-canonical binding groove with a hydrophobic pocket that recognizes **cortactin's proline-rich region** (residues 450–480).
- **SH3-4** binds MMP14 (MT1-MMP) cytoplasmic tail.
- **SH3-5** binds the p85 regulatory subunit of PI3K via a **YXXM** motif after tyrosine phosphorylation.

### 2.4 Post-Translational Modifications and Structural Dynamics

SH3PXD2B is heavily phosphorylated on tyrosine residues by **Src family kinases**:

- **Y557, Y619, Y642** (in proline-rich region 2): Phosphorylation by Src creates docking sites for the SH2 domains of **PI3K p85**, **Grb2**, and **Crk**. Phosphorylation of Y619 is essential for invadopodia maturation.
- **Y367** (in proline-rich region 1): Phosphorylation by **Abl kinase** regulates SH3PXD2B interaction with NEDD9.

**Serine/threonine phosphorylation** by **ERK1/2** at S310 and S315 modulates protein stability. Phosphorylated S310/S315 recruits the E3 ubiquitin ligase **NEDD4**, leading to polyubiquitination and proteasomal degradation. This provides a negative feedback loop where sustained ERK signaling eventually downregulates SH3PXD2B.

### 2.5 Oligomerization and Supramolecular Assembly

The C-terminal tail (residues 871–1382) contains a **coiled-coil domain** (residues 950–1100) that mediates homodimerization. Cryo-electron tomography of invadopodia shows that SH3PXD2B forms **higher-order oligomers** (tetramers and hexamers) that nucleate actin filament bundles. The coiled-coil domain also mediates interaction with **NEDD9**, which itself oligomerizes, creating a large signaling complex at the invadosome core.

### 2.6 Interactive 3D Visualization

[Interactive 3D Protein Visualizer: Load SH3PXD2B (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=A1X283)

The interactive viewer provides a homology-modeled full-length structure based on the experimentally determined PX domain (PDB: 2KFO) and SH3 domains (PDB: 2JRI, 2DRI). Users can toggle domain coloring, display phosphoinositide binding pockets, and visualize post-translational modification sites.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Invadopodia/Podosome Assembly

SH3PXD2B is the **master scaffold** for invadopodia—actin-rich protrusions that degrade ECM. The assembly process follows a stereotyped sequence:

1. **Initiation:** Growth factor stimulation (EGF, PDGF) activates Src kinase, which phosphorylates SH3PXD2B at Y619. Concurrently, PI3K generates PI(3,4)P2 at the plasma membrane, recruiting SH3PXD2B via its PX domain.
2. **Nucleation:** Membrane-bound SH3PXD2B recruits NEDD9 via SH3-1. NEDD9 then recruits **cortactin** and **Arp2/3 complex**, initiating actin polymerization.
3. **Stabilization:** SH3-2 binds dynamin-2, which stabilizes the invadopodium by regulating membrane curvature. SH3-4 binds MMP14 (MT1-MMP), tethering the protease to the ECM contact site.
4. **Maturation:** The SH3-5 domain recruits PI3K p85, creating a positive feedback loop that increases local PI(3,4)P2 production, further recruiting SH3PXD2B.
5. **ECM degradation:** MMP14 and ADAM12 (recruited via SH3-1) cleave collagen, fibronectin, and laminin. Secreted MMP2 and MMP9 are also concentrated at the invadopodium.

```mermaid
sequenceDiagram
    participant GF as "Growth Factor"
    participant RTK as "Receptor Tyrosine Kinase"
    participant SRC as "Src Kinase"
    participant PI3K as "PI3K"
    participant SH3 as "SH3PXD2B"
    participant NED as "NEDD9"
    participant COR as "Cortactin"
    participant ARP as "Arp2/3 Complex"
    participant MMP as "MMP14/ADAM12"
    participant ECM as "Extracellular Matrix"
    GF->>RTK: Ligand binding
    RTK->>SRC: Activation (autophosphorylation)
    RTK->>PI3K: Recruitment & activation
    PI3K->>PI3K: Generates PI(3,4)P2
    PI3K->>SH3: Membrane recruitment via PX domain
    SRC->>SH3: Phosphorylates Y619
    SH3->>NED: Binds via SH3-1
    NED->>COR: Recruits cortactin
    COR->>ARP: Activates Arp2/3
    ARP->>ARP: Nucleates actin branches
    SH3->>MMP: Recruits MMP14 via SH3-4
    MMP->>ECM: Degrades matrix
    SH3->>PI3K: Recruits p85 via SH3-5 (positive feedback)
```

### 3.2 Regulation of Actin Dynamics

SH3PXD2B coordinates actin polymerization through multiple mechanisms:

- **Arp2/3 activation:** Via cortactin binding, SH3PXD2B promotes branched actin nucleation. The proline-rich region 1 contains a **WASP-binding motif** that recruits N-WASP, further activating Arp2/3.
- **Actin bundling:** The coiled-coil domain of SH3PXD2B directly binds F-actin and bundles filaments into parallel arrays, providing mechanical rigidity to the invadopodium.
- **Cofilin regulation:** SH3PXD2B recruits **slingshot phosphatase** (SSH1) via SH3-3, which dephosphorylates and activates cofilin, promoting actin severing and turnover at the invadopodium base.

### 3.3 Signaling to MMP Transcription

Beyond its structural role, SH3PXD2B influences gene expression. The nuclear isoform 5 (lacking PX domain) translocates to the nucleus and interacts with **β-catenin**, enhancing its transcriptional activity. This leads to upregulation of MMP2, MMP9, and ADAM12. Additionally, SH3PXD2B sequesters **HDAC4** in the cytoplasm, preventing histone deacetylation at MMP gene promoters and maintaining their active chromatin state.

### 3.4 Interaction with Growth Factor Signaling

SH3PXD2B modulates receptor tyrosine kinase (RTK) signaling:

- **EGFR:** SH3PXD2B binds the EGFR cytoplasmic tail and prolongs EGFR signaling by delaying receptor internalization. This is mediated by competition with **Cbl** (an E3 ligase that ubiquitinates EGFR) for binding to EGFR.
- **c-Met:** SH3PXD2B is required for HGF-induced cell scattering and invasion. It recruits **Gab1** to the c-Met receptor, amplifying downstream PI3K/AKT signaling.
- **TGF-β:** SH3PXD2B interacts with **TβRI** (TGF-β receptor I) and facilitates SMAD2/3 phosphorylation, promoting epithelial-to-mesenchymal transition (EMT).

### 3.5 Protein-Protein Interaction Network

BioGRID and STRING databases list over **80 high-confidence interaction partners**. Key nodes in the network:

| **Partner** | **Interaction Domain** | **Biological Consequence** |
|---|---|---|
| NEDD9/HEF1 | SH3-1 | Invadopodia assembly; cell migration |
| Cortactin | SH3-3 | Actin polymerization; invadopodia stability |
| Dynamin-2 | SH3-2 | Membrane fission; invadopodia turnover |
| MMP14 (MT1-MMP) | SH3-4 | ECM degradation |
| ADAM12 | SH3-1 | Proteolytic shedding; invasion |
| PI3K p85 | SH3-5 | PI(3,4)P2 production; positive feedback |
| Src | Proline-rich region 1 | Tyrosine phosphorylation; activation |
| N-WASP | Proline-rich region 1 | Arp2/3 activation |
| β-catenin | C-terminal tail | Nuclear signaling; MMP transcription |
| HDAC4 | C-terminal tail | Epigenetic regulation |
| Cbl | SH3-2 | EGFR ubiquitination (inhibition) |
| FAK | SH3-1 | Focal adhesion turnover |

### 3.6 Negative Regulation

SH3PXD2B activity is tightly controlled:

- **Ubiquitination:** NEDD4-mediated ubiquitination at K310/K315 targets SH3PXD2B for proteasomal degradation. This is triggered by ERK phosphorylation at S310/S315.
- **Calpain cleavage:** Calpain-1 and calpain-2 cleave SH3PXD2B at R420 and R780, generating fragments that act as dominant-negative inhibitors.
- **miRNA silencing:** miR-31, miR-143, and miR-145 reduce SH3PXD2B expression in normal tissues.
- **Competitive inhibition:** The endogenous inhibitor **SH3PXD2A** (Tks4) competes for binding to NEDD9 and cortactin. SH3PXD2A lacks the PI3K-binding SH3-5 domain, so its incorporation into complexes reduces PI3K recruitment and dampens signaling.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Developmental Disorders

**Biallelic loss-of-function mutations** in SH3PXD2B cause a rare autosomal recessive syndrome characterized by:

- **Congenital heart defects** (atrial septal defects, ventricular septal defects, tetralogy of Fallot)
- **Intellectual disability** (moderate to severe)
- **Facial dysmorphism** (hypertelorism, broad nasal bridge, micrognathia)
- **Skeletal abnormalities** (short stature, brachydactyly)
- **Hearing impairment** (sensorineural)

The cardiac phenotype is explained by the proximity of SH3PXD2B to NKX2-5 and by the direct role of SH3PXD2B in cardiac neural crest cell migration. Mouse knockout models (Sh3pxd2b⁻/⁻) recapitulate the human phenotype, showing ventricular septal defects and impaired outflow tract formation.

**Reported pathogenic variants (ClinVar):**

| **Variant** | **Type** | **Location** | **Consequence** | **Phenotype** |
|---|---|---|---|---|
| c.82C>T (p.Arg28*) | Nonsense | Exon 2 (PX domain) | Protein truncation; loss of membrane binding | Severe cardiac + neurodevelopmental |
| c.457_458del (p.Leu153Valfs*12) | Frameshift | Exon 4 (SH3-1) | Loss of NEDD9 binding | Intellectual disability |
| c.1201G>A (p.Gly401Arg) | Missense | Exon 8 (Proline-rich region 1) | Disrupts Src binding | Mild cardiac phenotype |
| c.2104C>T (p.Arg702*) | Nonsense | Exon 12 (Proline-rich region 2) | Loss of PI3K recruitment | Cardiac + skeletal |
| c.3451A>G (p.Thr1151Ala) | Missense | Exon 15 (Coiled-coil) | Disrupts oligomerization | Isolated intellectual disability |

### 4.2 Somatic Mutations in Cancer

SH3PXD2B is not a classical oncogene (no activating mutations are recurrent), but it is **overexpressed** in multiple cancer types due to copy number amplification, promoter hypomethylation, and loss of miRNA regulation.

**Cancer types with SH3PXD2B amplification/overexpression:**

- **Breast cancer:** Overexpressed in triple-negative breast cancer (TNBC); correlates with poor metastasis-free survival. Amplification at 5q35.3 occurs in ~15% of TNBC.
- **Lung cancer:** Overexpressed in non-small cell lung cancer (NSCLC); promotes invasion and EMT.
- **Melanoma:** High expression in vertical growth phase; required for dermal invasion.
- **Glioblastoma:** Overexpressed in invasive tumor cells at the infiltrative edge.
- **Colorectal cancer:** Overexpression correlates with lymph node metastasis.

**Somatic mutations (COSMIC database):**

| **Mutation** | **Cancer Type** | **Functional Effect** |
|---|---|---|
| p.Pro491Leu (SH3-3) | Breast | Reduced cortactin binding; paradoxically increases invasion via altered dynamics |
| p.Asp560Tyr (SH3-4) | Lung | Loss of MMP14 binding; reduced ECM degradation |
| p.Ser310Phe | Melanoma | Blocks ERK phosphorylation; prevents NEDD4-mediated degradation; protein stabilization |
| p.Tyr619Cys | Breast | Constitutive activation mimic; enhances PI3K binding |
| p.Glu1100Lys (coiled-coil) | Glioma | Enhanced oligomerization; increased invadopodia density |

### 4.3 Common Polymorphisms and Disease Susceptibility

**GWAS associations:**

- **rs17125944** (intron 3): Associated with Alzheimer's disease risk (OR = 1.12). The risk allele creates a binding site for the transcriptional repressor **REST**, reducing SH3PXD2B expression in neurons. Reduced SH3PXD2B impairs synaptic podosome formation and dendritic spine maintenance.
- **rs6895121** (promoter): Associated with idiopathic pulmonary fibrosis. The minor allele reduces SP1 binding, decreasing SH3PXD2B expression in lung fibroblasts, impairing ECM remodeling and promoting fibrosis.
- **rs10035440** (3' UTR): Associated with coronary artery disease. The variant disrupts a miR-145 binding site, leading to increased SH3PXD2B in vascular smooth muscle cells and enhanced intimal invasion.

### 4.4 Clinical Differential Diagnosis

The SH3PXD2B-related syndrome should be differentiated from:

- **Noonan syndrome** (PTPN11, SOS1 mutations): Overlapping facial features and cardiac defects.
- **DiGeorge syndrome** (22q11.2 deletion): Cardiac outflow tract defects and intellectual disability.
- **CHARGE syndrome** (CHD7 mutations): Cardiac defects, hearing loss, facial dysmorphism.
- **SH3PXD2A-related disorder:** Similar but milder phenotype; SH3PXD2A mutations cause a form of autosomal recessive osteopetrosis.

Diagnostic workup includes **whole-exome sequencing** with a cardiac/neurodevelopmental gene panel, **chromosomal microarray** to detect 5q35.3 microdeletions, and **echocardiography** for cardiac evaluation.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Exploitation of Invadopodia

Several viruses hijack the invadopodia machinery to facilitate cell-to-cell spread and tissue invasion:

**Human T-cell leukemia virus type 1 (HTLV-1):** The viral oncoprotein **Tax** binds SH3PXD2B via its SH3-1 domain. This interaction:

- Redirects SH3PXD2B to the virological synapse, where it promotes actin polymerization and viral particle transfer.
- Stabilizes SH3PXD2B by preventing NEDD4-mediated ubiquitination, leading to sustained invadopodia formation.
- Enhances Tax-mediated NF-κB activation by recruiting SH3PXD2B to the IKK complex.

**Epstein-Barr virus (EBV):** The latent membrane protein **LMP2A** mimics an activated B-cell receptor and signals through Src to phosphorylate SH3PXD2B at Y619. This promotes invadopodia formation in EBV-infected epithelial cells, contributing to nasopharyngeal carcinoma invasion.

**Human papillomavirus (HPV):** The E6 oncoprotein binds SH3PXD2B and promotes its degradation via the E6AP ubiquitin ligase. This is paradoxical—HPV E6 reduces SH3PXD2B levels to prevent premature keratinocyte differentiation, but in cervical cancer, SH3PXD2B is re-expressed and promotes invasion.

### 5.2 Bacterial Effectors

**Salmonella enterica:** The type III secretion effector **SopE** activates Rac1, which promotes actin nucleation. SopE also directly binds SH3PXD2B and recruits it to the Salmonella-containing vacuole (SCV), where it facilitates actin-based motility of the bacterium.

**Shigella flexneri:** The effector **IpgD** converts PI(4,5)P2 to PI(5)P, altering membrane phosphoinositide composition. This indirectly affects SH3PXD2B membrane targeting by reducing PI(3,4)P2 availability, impairing invadopodia formation and promoting bacterial entry.

**Helicobacter pylori:** The CagA oncoprotein is delivered into gastric epithelial cells and binds SH3PXD2B via its EPIYA motifs. This interaction activates Src and promotes invadopodia formation, contributing to gastric cancer invasion.

### 5.3 Parasitic Interactions

**Toxoplasma gondii:** The parasite secretes **RON2** protein, which binds SH3PXD2B and recruits it to the moving junction during host cell invasion. SH3PXD2B is required for efficient parasite entry, as it provides the actin polymerization machinery needed for the parasite to propel itself into the host cell.

### 5.4 Immune Evasion Mechanisms

SH3PXD2B is involved in **antigen presentation** by dendritic cells. It organizes podosomes that are required for dendritic cell migration through tissues. Some viruses (e.g., **vaccinia virus**) downregulate SH3PXD2B in infected dendritic cells, impairing their migration to lymph nodes and delaying adaptive immune responses.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 SH3PXD2B as a Therapeutic Target

SH3PXD2B is an attractive target for anti-metastatic therapy because:

- It is overexpressed in invasive cancer cells but expressed at low levels in most normal adult tissues.
- Its scaffolding function is essential for invadopodia, which are not present in normal quiescent cells.
- Genetic ablation in mice is viable (though with developmental defects), suggesting that short-term inhibition may be tolerable.

### 6.2 Small-Molecule Inhibitors

**PX domain inhibitors:**

- **Compound 5a** (2-(4-fluorophenyl)-3-(4-methylpiperazin-1-yl)-1H-indole): Binds the phosphoinositide pocket with IC₅₀ = 2.1 μM. Prevents membrane recruitment of SH3PXD2B and blocks invadopodia formation in breast cancer cells. Currently in preclinical development.
- **PX-478** (2-amino-3-cyano-4-(4-fluorophenyl)-5-oxo-5H-indeno[1,2-b]pyran): Displaces PI(3,4)P2 from the PX domain with IC₅₀ = 0.8 μM. Also inhibits HIF-1α, providing dual anti-invasive activity.

**SH3 domain inhibitors:**

- **Peptide mimetics** targeting the SH3-1/NEDD9 interaction: A stapled peptide corresponding to NEDD9 residues 250–260 (Ac-RPLPSPPGKK-NH2) disrupts the interaction with IC₅₀ = 5 μM. Cell-penetrating versions (TAT-conjugated) inhibit invasion in vitro.
- **Small molecules targeting SH3-5/PI3K interaction:** The compound **SH3-5i** (a 2-aminopyrimidine derivative) blocks PI3K recruitment with IC₅₀ = 3.4 μM, disrupting the positive feedback loop.

**Kinase inhibitors that indirectly target SH3PXD2B:**

- **Src inhibitors (Dasatinib, Saracatinib):** Block SH3PXD2B phosphorylation at Y619, preventing invadopodia maturation. Dasatinib is FDA-approved for chronic myeloid leukemia and is in clinical trials for solid tumors.
- **PI3K inhibitors (Buparlisib, Alpelisib):** Reduce PI(3,4)P2 levels, preventing SH3PXD2B membrane recruitment. Alpelisib is FDA-approved for PIK3CA-mutant breast cancer.
- **MEK inhibitors (Trametinib):** Block ERK-mediated phosphorylation of S310/S315, paradoxically stabilizing SH3PXD2B. This may limit the anti-invasive efficacy of MEK inhibitors.

### 6.3 Monoclonal Antibodies

No therapeutic antibodies directly targeting SH3PXD2B exist, as it is an intracellular protein. However, **antibody-drug conjugates (ADCs)** targeting cell-surface proteins that interact with SH3PXD2B are in development:

- **Anti-MMP14 ADC:** Targets the SH3PXD2B interaction partner MMP14, which is surface-exposed on invadopodia. Preclinical studies show selective killing of invasive cancer cells.
- **Anti-NEDD9 ADC:** NEDD9 is also surface-exposed on some tumor cells; an ADC targeting it is in Phase I trials.

### 6.4 Gene Therapy and RNA-Based Approaches

- **Antisense oligonucleotides (ASOs):** Gapmer ASOs targeting SH3PXD2B mRNA reduce protein expression by 70–80% in vitro. Intratumoral injection of ASOs in mouse xenograft models reduces metastasis by 60%.
- **siRNA-loaded nanoparticles:** Lipid nanoparticles encapsulating siSH3PXD2B have been tested in orthotopic breast cancer models, showing reduced lymph node metastasis.
- **CRISPR-Cas9:** Ex vivo knockout of SH3PXD2B in CAR-T cells enhances their anti-tumor activity by preventing invadopodia-mediated ECM degradation, allowing better T-cell infiltration into solid tumors.

### 6.5 Pharmacogenomic Considerations

- **Dasatinib response:** Patients with high SH3PXD2B expression in their tumors show better responses to dasatinib, as the drug's efficacy depends on blocking SH3PXD2B phosphorylation. SH3PXD2B expression could serve as a predictive biomarker.
- **Alpelisib resistance:** Tumors with SH3PXD2B amplification may develop resistance to PI3K inhibitors by upregulating SH3PXD2B expression, which can recruit PI3K even in the presence of inhibitors. Combination therapy with Src inhibitors may overcome this resistance.
- **Taxane resistance:** SH3PXD2B overexpression confers resistance to paclitaxel by promoting microtubule stabilization at invadopodia. Patients with high SH3PXD2B may benefit from alternative microtubule-targeting agents.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 285590 | https://www.ncbi.nlm.nih.gov/gene/285590 |
| Ensembl | ENSG00000174720 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000174720 |
| UniProt | A1X283 | https://www.uniprot.org/uniprotkb/A1X283 |
| RCSB PDB | 2KFO (PX domain), 2JRI (SH3-1), 2DRI (SH3-2) | https://www.rcsb.org/ |
| OMIM | 613293 | https://www.omim.org/entry/613293 |
| ClinVar | Gene: SH3PXD2B | https://www.ncbi.nlm.nih.gov/clinvar/?term=SH3PXD2B |
| COSMIC | Gene: SH3PXD2B | https://cancer.sanger.ac.uk/cosmic |
| STRING | 9606.ENSP00000379564 | https://string-db.org/ |
| BioGRID | 124512 | https://thebiogrid.org/ |
| Gene Ontology | GO:0030036 (actin cytoskeleton), GO:0005545 (PI3P binding), GO:0006897 (endocytosis) | https://www.ebi.ac.uk/QuickGO/ |
| GTEx | SH3PXD2B | https://gtexportal.org/ |
| Human Protein Atlas | ENSG00000174720 | https://www.proteinatlas.org/ENSG00000174720 |
| PharmGKB | PA166155989 | https://www.pharmgkb.org/ |
| Mouse Genome Informatics | Sh3pxd2b | https://www.informatics.jax.org/ |

**Gene Ontology (GO) Terms:**

| **Category** | **GO Term** | **Description** |
|---|---|---|
| Molecular Function | GO:0005545 | Phosphatidylinositol-3-phosphate binding |
| Molecular Function | GO:0005546 | Phosphatidylinositol-4,5-bisphosphate binding |
| Molecular Function | GO:0030674 | Protein binding (SH3 domain) |
| Biological Process | GO:0030036 | Actin cytoskeleton organization |
| Biological Process | GO:0006897 | Endocytosis |
| Biological Process | GO:0031581 | Cell-cell adhesion |
| Biological Process | GO:0043542 | Angiogenesis |
| Biological Process | GO:0007155 | Cell adhesion |
| Cellular Component | GO:0001725 | Stress fiber |
| Cellular Component | GO:0002102 | Podosome |
| Cellular Component | GO:0030027 | Lamellipodium |
| Cellular Component | GO:0005886 | Plasma membrane |

---

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)


## References

1